SEC Company Response from INNOCAN PHARMA (INNPF) — Sep 24, 2025
INNOCAN PHARMA Corp
Date: Sept. 24, 2025 · CIK: 0001889791 · Accession: 0001493152-25-014762
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288899
Letter
Innocan Pharma Corporation
1015, 926 – 5 Avenue SW
Calgary, Alberta T2P 0N7, Canada
September 24, 2025
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
RE: Innocan Pharma Corporation (CIK 0001889791)
Registration Statement No. 333-288899 on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
Innocan Pharma Corporation (the “Registrant”) hereby withdraws its request submitted on September 22, 2025 for acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), on September 24, 2025 at 5:00 p.m., Eastern Time.
Very
truly yours,
INNOCAN
PHARMA CORPORATION
Show Raw Text
CORRESP
1
filename1.htm
Innocan
Pharma Corporation
1015,
926 – 5 Avenue SW
Calgary,
Alberta T2P 0N7, Canada
September
24, 2025
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
DC 20549
RE:
Innocan
Pharma Corporation (CIK 0001889791)
Registration
Statement No. 333-288899 on Form F-1 (the “Registration Statement”)
Ladies
and Gentlemen:
Innocan
Pharma Corporation (the “Registrant”) hereby withdraws its request submitted on September 22, 2025 for acceleration
of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended
(the “Securities Act”), on September 24, 2025 at 5:00 p.m., Eastern Time.
Very
truly yours,
INNOCAN
PHARMA CORPORATION
By:
/s/
Iris Bincovich
Iris
Bincovich
Chief
Executive Officer
cc:
David Huberman (Greenberg Traurig, LLP)